BlackRock Group’s Ocular Therapeutix OCUL Stock Holding History

BlackRock Group’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-13,142	Closed	-$90K	–	2994
2016 Q3	$90K	Hold	13,142	–	–	﹤0.01%	2835
2016 Q2	$65K	Hold	13,142	–	–	﹤0.01%	2877
2016 Q1	$127K	Buy	13,142 +11,926	+981%	+$90.3K	﹤0.01%	2690
2015 Q4	$11K	Hold	1,216	–	–	﹤0.01%	2988
2015 Q3	$17K	Buy	+1,216	New	+$24.4K	﹤0.01%	2996
2014 Q4	–	Sell	-5,487	Closed	-$82K	–	2902
2014 Q3	$82K	Buy	+5,487	New	+$81.1K	﹤0.01%	2615

Other funds holding OCUL

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PVMCV

Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

CCI

Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return

BlackRock Group's OCUL Position: Q4 2016 in Review

BlackRock Group sold out of Ocular Therapeutix (OCUL) in Q4 2016, closing a stake of 13,142 shares — an estimated $90K sold.

BlackRock Group first reported a position in OCUL in Q3 2014 and held it in 6 quarters. The position peaked at $127K in Q1 2016. 76 funds tracked by Wall St. Rank hold OCUL as of Q4 2016.

BlackRock Group reported no remaining Ocular Therapeutix position as of Q4 2016 after selling out during the quarter.
BlackRock Group sold 13,142 Ocular Therapeutix shares in Q4 2016, an estimated $90K.
BlackRock Group first reported a position in Ocular Therapeutix in Q3 2014 and held it in 6 quarters.
BlackRock Group's Ocular Therapeutix position peaked at $127K in Q1 2016.
76 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.